93 related articles for article (PubMed ID: 21054985)
21. ERCC1 predicts outcome in patients with gastric cancer treated with adjuvant cisplatin-based chemotherapy.
De Dosso S; Zanellato E; Nucifora M; Boldorini R; Sonzogni A; Biffi R; Fazio N; Bucci E; Beretta O; Crippa S; Saletti P; Frattini M
Cancer Chemother Pharmacol; 2013 Jul; 72(1):159-65. PubMed ID: 23645290
[TBL] [Abstract][Full Text] [Related]
22. [GRP78 expression in gastric cancer and its clinical significance].
Yang L; Yang SY; Ji JM; Cao YF; Ji CF; Ji JF; Xu WW; Wang JH
Zhonghua Zhong Liu Za Zhi; 2013 Nov; 35(11):837-42. PubMed ID: 24447482
[TBL] [Abstract][Full Text] [Related]
23. Impact of E2F-1 expression on clinical outcome of gastric adenocarcinoma patients with adjuvant chemoradiation therapy.
Lee J; Park CK; Park JO; Lim T; Park YS; Lim HY; Lee I; Sohn TS; Noh JH; Heo JS; Kim S; Lim DH; Kim KM; Kang WK
Clin Cancer Res; 2008 Jan; 14(1):82-8. PubMed ID: 18172256
[TBL] [Abstract][Full Text] [Related]
24. Synergistic antitumor effects of dasatinib and oxaliplatin in gastric cancer cells.
Shi M; Lou B; Ji J; Shi H; Zhou C; Yu Y; Liu B; Zhu Z; Zhang J
Cancer Chemother Pharmacol; 2013 Jul; 72(1):35-44. PubMed ID: 23712327
[TBL] [Abstract][Full Text] [Related]
25. Expression and significance of S100P, CD147, and OCT4 in different prostate cancer tissue TNM stages.
Wang Q; Zhang JG; Wang W
Genet Mol Res; 2015 Jun; 14(2):6844-51. PubMed ID: 26125892
[TBL] [Abstract][Full Text] [Related]
26. Macrophage migration inhibitory factor as a potential prognostic factor in gastric cancer.
He LJ; Xie D; Hu PJ; Liao YJ; Deng HX; Kung HF; Zhu SL
World J Gastroenterol; 2015 Sep; 21(34):9916-26. PubMed ID: 26379396
[TBL] [Abstract][Full Text] [Related]
27. S100P, a potential novel prognostic marker in colorectal cancer.
Wang Q; Zhang YN; Lin GL; Qiu HZ; Wu B; Wu HY; Zhao Y; Chen YJ; Lu CM
Oncol Rep; 2012 Jul; 28(1):303-10. PubMed ID: 22552710
[TBL] [Abstract][Full Text] [Related]
28. Comparison of capecitabine and oxaliplatin with S-1 as adjuvant chemotherapy in stage III gastric cancer after D2 gastrectomy.
Cho JH; Lim JY; Cho JY
PLoS One; 2017; 12(10):e0186362. PubMed ID: 29040299
[TBL] [Abstract][Full Text] [Related]
29. [Clinical analysis of the current treatment status of gastric cancer in 636 patients].
Zhuang QX; Xu JM; Lin L; Ge FJ; Liu LJ; Wang Y; Zhao CH
Zhonghua Zhong Liu Za Zhi; 2012 Apr; 34(4):316-20. PubMed ID: 22781048
[TBL] [Abstract][Full Text] [Related]
30. S100P, a calcium-binding protein, is preferentially associated with the growth of polypoid tumors in colorectal cancer.
Chiang JM; Tan R; Wang JY; Chen JS; Lee YS; Hsieh PS; Changchien CR; Chen JR
Int J Mol Med; 2015 Mar; 35(3):675-83. PubMed ID: 25585623
[TBL] [Abstract][Full Text] [Related]
31. [Inducement of FLICE inhibitory protein antisense oligonucleotides on apoptosis of human gastric cancer cell line BGC823].
Zhang GQ; Pang D; Wang K; Xue YW; Zhang QF; Zhao JH
Ai Zheng; 2004 Nov; 23(11 Suppl):1390-5. PubMed ID: 15566642
[TBL] [Abstract][Full Text] [Related]
32. [Expression of phosphatase of regenerating liver-3 in gastric cancer, its relationship with prognosis, and its role in gastric cancer cell proliferation].
Cai SR; Chen CQ; Wang Z; He YL; Cui J; Wu WH; Wu H; Zhan WH
Zhonghua Yi Xue Za Zhi; 2008 Aug; 88(33):2326-30. PubMed ID: 19087692
[TBL] [Abstract][Full Text] [Related]
33. [Clinical features and prognosis analysis of 21 gastric cancer patients with pathological complete response after neoadjuvant chemotherapy].
Peng L; Yang W; Zhang Z; Liu H; Hua Y
Zhonghua Wei Chang Wai Ke Za Zhi; 2017 Oct; 20(10):1168-1173. PubMed ID: 29130233
[TBL] [Abstract][Full Text] [Related]
34. miRNA27a is a biomarker for predicting chemosensitivity and prognosis in metastatic or recurrent gastric cancer.
Huang D; Wang H; Liu R; Li H; Ge S; Bai M; Deng T; Yao G; Ba Y
J Cell Biochem; 2014 Mar; 115(3):549-56. PubMed ID: 24122958
[TBL] [Abstract][Full Text] [Related]
35. [Effects of traditional Tibetan drug Liu Tea on proliferation and chemotherapeutic sensitivity of drug-resistant human gastric cancer cell BGC823/5-FU].
Cheng Y; Hasiqi MG; Qin XZ; Tang XY; Chen JN; Wang HY; Gao A
Zhongguo Zhong Yao Za Zhi; 2016 Feb; 41(4):603-608. PubMed ID: 28871679
[TBL] [Abstract][Full Text] [Related]
36. S100P and HYAL2 as prognostic markers for patients with triple-negative breast cancer.
Maierthaler M; Kriegsmann M; Peng C; Jauch S; Szabo A; Wallwiener M; Rom J; Sohn C; Schneeweiss A; Sinn HP; Yang R; Burwinkel B
Exp Mol Pathol; 2015 Aug; 99(1):180-7. PubMed ID: 26112095
[TBL] [Abstract][Full Text] [Related]
37. [Construction of RNAi targeting TRAF1 gene and effect of TRAF1 on gastric cancer cells].
Wang F; Yang Y; Feng Q; Bu G; Huang L; Lu H; Guo Q; Xu C; Shen S
Zhong Nan Da Xue Xue Bao Yi Xue Ban; 2012 Sep; 37(9):876-82. PubMed ID: 23000760
[TBL] [Abstract][Full Text] [Related]
38. Short-term curative effect of S-1 plus oxaliplatin as perioperative chemotherapy for locally advanced gastric cancer: a prospective comparison study.
Zhao Q; Li Y; Huang J; Fan L; Tan B; Tian Y; Yang P; Jiao Z; Zhao X; Zhang Z; Wang D; Liu Y
Pharmazie; 2017 Apr; 72(4):236-240. PubMed ID: 29441995
[TBL] [Abstract][Full Text] [Related]
39. Role of the MTT chemosensitivity test in the prognosis of gastric cancer patients after postoperative adjuvant chemotherapy.
Nakamura R; Saikawa Y; Kubota T; Kumagai A; Kiyota T; Ohashi M; Yoshida M; Otani Y; Kumai K; Kitajima M
Anticancer Res; 2006; 26(2B):1433-7. PubMed ID: 16619555
[TBL] [Abstract][Full Text] [Related]
40. Low expression of DLC1 is predictive of poor therapeutic efficiency of fluoropyrimidine and oxaliplatin as adjuvant chemotherapy in gastric cancer.
Su Y; Lin L; Zhang J; Jiang Y; Pan C; Sun L; Duan J; Liao W
Mol Med Rep; 2015 Oct; 12(4):5771-9. PubMed ID: 26239822
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
